Loyola University Chicago

Loyola eCommons
Master's Theses

Theses and Dissertations

2012

Urinary Antimicrobial Peptides and the Urinary Microbiota in a
UTI-Susceptible Population of Female Pelvic Floor Surgery
Patients
Vanessa Nienhouse
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_theses
Part of the Immunology and Infectious Disease Commons

Recommended Citation
Nienhouse, Vanessa, "Urinary Antimicrobial Peptides and the Urinary Microbiota in a UTI-Susceptible
Population of Female Pelvic Floor Surgery Patients" (2012). Master's Theses. 727.
https://ecommons.luc.edu/luc_theses/727

This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It
has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2012 Vanessa Nienhouse

LOYOLA UNIVERSITY CHICAGO

URINARY ANTIMICROBIAL PEPTIDES AND THE URINARY MICROBIOTA IN A
UTI-SUSCEPTIBLE POPULATION OF FEMALE PELVIC FLOOR SURGERY PATIENTS

A THESIS SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
MASTER OF SCIENCE

PROGRAM IN INFECTIOUS DISEASE AND IMMUNOLOGY

BY
VANESSA LAUREN NIENHOUSE
CHICAGO, ILLINOIS
MAY 2012

Copyright by Vanessa Lauren Nienhouse, 2012
All rights reserved.

For Gracie.

ACKNOWLEDGEMENTS
I would like to thank my two basic science mentors, Dr. Alan Wolfe and Dr.
Katherine Radek, and my clinical mentor, Dr. Linda Brubaker, for their unshakable
support, encouragement and valuable guidance. Alan has provided much needed
support during the endless trouble-shooting phases, but also was not afraid to push me
and ask me to push myself to accomplish more than I ever thought I could. Katherine
has been a source of endless creative and innovative ideas and I thank her for graciously
taking me into her lab and envisioning this exciting project. Linda has served as an
excellent role model and an invaluable window into the clinical world, helping me to
truly make the most of the unique opportunities in this program. Additionally, I would
like to thank my committee chair, Dr. Adam Driks, for his generosity with his time and
advice.
I would not have accomplished any research without the support of every
member of the Wolfe and Radek labs. Noriko Shibata and Steve Droho were
instrumental in teaching me the basics of bench-work and I am extremely grateful for
their patience and good humor. Other members of the Radek lab, Dr. Jennifer Plichta,
Dr. Brenda Curtis and Tina Griffin have always been willing to lend a sympathetic ear,
offer advice and provide expertise. Student meetings in the Wolfe lab

iv

were some of the most productive times of my training, and I thank every student lab
member for all their input.
Many thanks go to the Infectious Disease and Immunology Institute, its codirectors Dr. Katherine Knight and Dr. David Hecht, and the graduate program director,
Dr. Karen Visick, for making every effort to help us get the most out of this graduate
program and for valuing our feedback. Thank you also to Sara Hlavin and Michelle
Laning, my fellow students/guinea pigs for your camaraderie and moral support.
Lastly, but arguably most importantly, I am eternally grateful to my family,
Mommy, Daddy and Kyle; I could not ask for a more steadfast support system.

v

TABLE OF CONTENTS

ACKNOWLEDGEMENTS

iv

LIST OF FIGURES

vii

LIST OF ABBREVIATIONS

ix

ABSTRACT

xi

CHAPTER ONE: INTRODUCTION – LITERATURE REVIEW
Clinical Impact of Urinary Tract Infection
Host-Pathogen Interactions in the Urinary Tract
Relevance of the Microbiota
Antimicrobial Peptides
Concluding Remarks

1
1
5
7
11
17

CHAPTER TWO: MATERIALS AND METHODS
Sample Collection and Processing
Enzyme-Linked Immunosorbent Assays (ELISA)
High Pressure Liquid Chromotography (HPLC)
Radial Diffusion Assay (RDA)
Protease Assay
16S Sequencing and Bioinformatics
Statistical Analyses

18
18
19
20
20
21
21
22

CHAPTER THREE: EXPERIMENTAL RESULTS
Urinary Antimicrobial Peptide Levels
Urinary Antimicrobial Peptide Activity
Urinary Microbiota
Integrated AMP and Microbiota Results

23
22
28
36
41

CHAPTER FOUR: DISCUSSION
Sample Processing
Urinary Antimicrobial Peptides
Urinary Microbiota
Integrated Analyses

44
44
47
50
54

REFERENCE LIST

58

VITA

66
vi

LIST OF FIGURES

Figure
1. Protein assay comparison with the same samples reveals discrepancies
between assays

25

2. Urinary antimicrobial peptides human β-defensin-1 and psoriasin
exhibit great variability.

27

3. Antimicrobial peptides and urinary peptides elute at various acetonitrile
concentrations during HPLC.

29

4. Baseline-positive urine tends to contain a greater variety and higher
concentrations of protein and peptides than baseline-negative urine.

32

5. Baseline-positive urinary peptide fractions exhibit greater antimicrobial
activity.

33

6. Urinary protease activity trends toward higher levels in baseline-positive
urine than in baseline-negative urine.

35

7. Genetic diversity of urinary microbiota.

37

8. Microbiota profiles of postI-UTI and baseline-positive samples at the
family level are similar.

39

9. Microbiota profiles postI-UTI samples at the genus level are similar.

40

10. Levels of psoriasin are lower in urine with detectable E. coli than in urine
with other types of infection.

42

vii

11. The number of sequences in the genera Streptococcus and Peptoniphilus
each positively correlate with levels of psoriasin.

viii

43

LIST OF ABBREVIATIONS

µg
µm
°C
AAD
ACN
AMP
ANOVA
BCA
BLAST
BSA
DAMP
DNA
ELISA
GI
h-BD
HRP
HPLC
H2SO4
IC/BPS
IL
kD
LL-37
mL
NF-κB
nm
OTU
PAMP
PCR
POP
PostI-UTI

microgram
micrometer
degrees celcius
antibiotic-associated diarrhea
acetonitrile
antimicrobial peptide
analysis of variance
bicinchoninic acid
basic local alignment tool
bovine serum albumin
danger-associated molecular pattern
deoxyribonucleic acid
enzyme-linked immunosorbent assay
gastrointestinal
human beta-defensin
horseradish peroxidase
high-pressure liquid chromatography
sulfuric acid
interstitial cystitis/bladder pain syndrome
interleukin
kilodalton
cathelicidin
milliliter
nuclear factor kappa-light-chain-enhancer of activated B cells
nanometer
operational taxonomic unit
pathogen-associated molecular pattern
polymerase chain reaction
pelvic organ prolapse
post-instrumentation urinary tract infection
ix

RDA
RDP
RNA
TFA
TGF-β
TLR
UI
UPEC
UTI
VDRE

radial diffusion assay
ribosomal database project
ribonucleic acid
trifluoroacetic acid
transforming growth factor-beta
toll-like receptor
urinary incontinence
uropathogenic E. coli
urinary tract infection
vitamin D response element

x

ABSTRACT
Urinary tract infections (UTI)s are a national priority. Women who undergo
surgery for pelvic floor disorders such as pelvic organ prolapse (POP) or urinary
incontinence (UI) are at increased risk for UTI, as 10-30% will contract a postinstrumentation UTI (postI-UTI) within six weeks after surgery. Currently, the factors
that contribute to the high rate of postI-UTI are unknown, and there is currently no
clinical assessment to identify at-risk patients. However, antimicrobial peptides (AMPs)
and characteristics of the urinary microbiota have the potential to serve as biomarkers,
identifying patients at UTI risk and facilitating clinical prevention studies.
While it was previously thought that the urinary tract was a sterile environment,
new evidence shows that bacteria inhabit the urinary tract in many people. Given that
microbial communities (microbiota) in other areas of the body exist in a balance with
the host defense system, a similar equilibrium likely exists between the microbiota and
host defenses in the urinary tract. AMPs, one significant component of our innate
defense system, can limit pathogenic infection by their abilities to interact with and
disrupt microbial membranes, and to stimulate immune cell recruitment. While it is
reported that certain AMPs are expressed in the urinary tract, the AMP profile of the
urinary tract has not been characterized. Inappropriate expression of AMPs in other
tissues, including altered levels and/or activity, has been associated with several
xi

different disease states. It is therefore possible that POP/UI surgery patients that
express inappropriate AMP levels or decreased AMP potency have an imbalance
between their defenses and their resident microbiota, which results in their
susceptibility to postI-UTI.
These results begin to reveal the urinary antimicrobial peptide and microbiota
profiles of three cohorts of patients: (1) POP/UI patients with culture-negative urine
samples at baseline who DO NOT develop a postI-UTI (2) POP/UI patients with culturenegative urine at baseline who DO develop a postI-UTI, and (3) POP/UI patients with
positive clinical cultures at baseline. While levels of two AMPs, psoriasin and human βdefensin-1, do not significantly differ between the cohorts, preliminary evidence
suggests that a characteristic microbiota may exist in patients who develop infection.
Furthermore, AMPs and the microbiota may directly influence one another. Levels of
psoriasin are lower in patients with detectable E. coli in their urine than in patients with
other types of infections. In addition to this correlation, the presence of certain genera
of bacteria positively correlates with levels of psoriasin. This could indicate that some
members of the microbiota, by affecting levels of AMPs, influence the susceptibility of
the urinary tract to invading pathogens. By furthering our understanding of urinary
AMPs and the urinary microbiota, we take an important step toward being able to
identify POP/UI patients who are at high risk for postI-UTI, and toward developing new
therapeutic options for preventing infection.
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CHAPTER ONE
INTRODUCTION - LITERATURE REVIEW
Clinical Impact of Urinary Tract Infections
Urinary tract infections (UTIs) are an important and costly clinical problem.
Different reports suggest that thirty to sixty percent of adult women will experience a
symptomatic UTI during their lifetime [1, 2]. In the US, it is estimated that there are over
eight million episodes of UTI per year [3], and the annual cost associated with the
treatment and care of UTIs is thought to exceed $2 billion [4]. Infections of the lower
urinary tract, where they are termed cystitis, are associated with symptoms of dysuria,
frequency, urgency, and lower abdominal or suprapubic pain [2]. Infections of the lower
urinary tract can ascend to the kidneys causing pyelonephritis with symptoms of fever,
costovertebral tenderness, nausea and vomiting [2]. Pyelonephritis can result in renal
scarring and renal failure and can progress to systemic infection and even death [1].
UTIs are considered uncomplicated if they occur in otherwise healthy nonpregnant women. UTIs are considered complicated when they occur in patients with
additional morbidity factors that could contribute to the failure of therapy, such as
structural or functional abnormalities of the urinary tract, history of renal stones, use of
catheters, infection with antibiotic-resistant organisms or being immunocompromised
[2, 3]. Using conventional clinical urine culture techniques to identify bacteria, the most
1
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common uropathogen is E. coli, which accounts for 80-85% of UTIs in premenopausal
women. In postmenopausal women and in women with complicated UTIs, other
uropathogens, such as K. pneumoniae, Staphylococcus saprophyticus, Proteus,
Pseudomonas, Enterobacter, Serratia and other Gram-negative enteric bacteria, are
common [2]. Many of these organisms frequently colonize the gastrointestinal tract and
infection of the urinary tract is thought to be preceded by colonization of the vagina and
then the periurethral area. The vaginal bacterial community plays a role in susceptibility
to UTI. For example, hydrogen-peroxide producing strains of lactobacillus that normally
inhabit the vagina inhibit the colonization of uropathogens and thereby help prevent
their transmittance from the gastrointestinal tract to the urinary tract [3].
Risk factors associated with higher rates of UTI include recent sexual intercourse,
use of spermicide-associated contraceptive methods [5] and possibly a shorter distance
between the urethra and the anus [1]. In addition, the association of a number of genes
with susceptibility to recurrent UTI suggests a possible genetic predisposition for risk of
infection. These genes encode CXCR1 (the alpha subunit of the IL-8 receptor) [6], CXCR2
(the beta subunit of the IL-8 receptor), TLR2, TLR4 and TGF-β1 (a cytokine with multiple
downstream effectors) [2]. All of these genes mediate either adaptive or innate immune
responses.
Patients undergoing corrective surgery for pelvic organ prolapse (POP) and/or
urinary incontinence (UI) are at increased risk for UTI. These surgery patients represent
a significant population; one study estimated that up to 50% of vaginally parous women
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lose pelvic floor support, resulting in prolapse, and found that the likelihood of a woman
undergoing a POP/UI procedure is 11.1% [7]. Reported rates of post-instrumentation
UTI (postI-UTI) vary depending on the definition used for UTI diagnosis. One study
reported a postI-UTI rate of 5.9% in UI patients undergoing midurethral sling
procedures, defining UTI as symptoms of UTI with a urine culture containing ≥50,000
cfu/mL of a single bacterial species within one month after surgery [8]. Another report
found a postI-UTI rate of 9% in POP/UI surgery patients, defining UTI as irritative voiding
symptoms accompanied by a positive urine culture within six weeks after surgery [9].
Finally, the SISTEr trial, which compared Burch colposuspension with autologous fascial
sling for the treatment of stress incontinence, and defined UTI as culture-proven
bladder infection or clinical suspicion of bladder infection resulting in treatment, found
the rate of postI-UTI to be 48% in patients undergoing the sling procedure and 32% in
the Burch procedure patients within twenty-four months after surgery [10]. Regardless
of the definition used, postI-UTI rates are still strikingly high.
PostI-UTIs remain a problem despite preventive actions, such as the use of
standard sterile technique during surgery, the administration of prophylactic antibiotics
at the time of surgery, and several defensive mechanisms employed by the female
urinary tract to prevent infection. These defensive mechanisms include shedding of
uroepithelial cells with adherent microorganisms, secretion of mucus from the
paraurethral glands to trap bacteria, and the intermittent wash-out of the urethra and
bladder by the flow of urine [11]. Given all of these defensive and preventive

4

mechanisms, it is currently not known why the prevalence of postI-UTI is so high. Some
patient characteristics have been identified as risk factors, such as elevated
preoperative postvoid residual volume [8], but no biomarkers have been identified that
could serve to identify patients at high risk for postI-UTI.
Although the high rate of postI-UTIs in this population of POP/UI surgery patients
is a clinical problem, their well-documented clinical characteristics and their known risk
make them ideal subjects for the study of UTIs. By recruiting POP/UI patients and
obtaining urine specimens before the time of surgery and thus before infection, we
have a unique opportunity to identify differences in the baseline status of patients who
ultimately come down with infection. Identifying who is at risk for infection will be an
important first step in understanding why these patients are at risk, and eventually
lead to the advent of better means of preventing infection.
It is likely that no single characteristic can be used as an identifying risk factor,
but rather that a number of factors play a role in indicating who is at risk. Urinary tract
infections are the result of dynamic interplay between host factors like the innate
immune system, pathogen factors like the expression of adhesins that aid bacteria in
attachment and invasion [12], and factors pertaining to the environment of the
genitourinary tract, such as the presence or absence of commensal bacterial species in
or around the urinary tract. We will need to study each of these factors in the context of
the others to fully understand the factors that contribute to risk for postI-UTI.

5

Host-Pathogen Interactions in the Urinary Tract
As described above, urinary tract infections are likely the outcome of dynamic
interactions between the host immune system, the pathogens, and other members of
the microbiota. Illustrative of these dynamics are several interactions that have been
elucidated between known uropathogens and the human urinary tract. One of the first
putative mechanisms of host defense that a pathogen will encounter in the urinary tract
is the outward flow of urine, making the ability to adhere to the uroepithelium an
important virulence factor. Uropathogens express a variety of adhesion molecules, e.g.
MR/P fimbriae expressed by Proteus mirabilis and Type-1 Pili expressed by
uropathogenic E. coli (UPEC) [6]. Type-1 pili bind uroplakin, a structural protein
expressed on the surfaces of uroepithelial cells, via the FimH adhesin located at the tip
of the pilus [12]. Both of these uropathogens also secrete toxins that contribute to
disease, express flagella that aid in motility and ascension of infection, and possess iron
acquisition systems [6].
The adhesive interaction of UPEC not only allows it to adhere to the mucosa, but
also results in the stimulation of various host defense responses. Upon binding by FimH,
superficial uroepithelial cells, which normally have a very slow turnover rate, are
stimulated to rapidly exfoliate and to be shed in the urine, taking any adherent
pathogens with them [13]. Additional innate defense factors include the typically low pH
and osmolarity of urine, which are not conducive for bacterial growth, and lactoferrin in
urine, which scavenges the iron necessary for bacterial growth. Other soluble defense
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factors include Tamm-Horsfall protein, low molecular weight sugars and secretory IgA,
all of which can bind to bacteria and inhibit their ability to adhere to the epithelial
surface [12, 14]. The FimH interaction with epithelial cell receptors, augmented by TLR4
detection of LPS, also induces uroepithelial cells to produce IL-6 and IL-8, which
subsequently activate a number of inflammatory pathways and recruit neutrophils,
respectively [12].
UPEC have developed mechanisms to evade these host defenses. Compared to
non-uropathogenic E. coli, UPEC elicit a less robust inflammatory response by avoiding
detection by pattern-recognition receptors and inhibiting the NF-κB mediated
expression of AMPs, pro-inflammatory cytokines and chemokines [15, 16]. The resulting
delay in neutrophil recruitment allows UPEC to gain an early foothold, invade epithelial
cells, and actually utilize the relative safety of the interior of those cells as an
environment to replicate and persist in biofilm-like communities out of which they may
periodically emerge. Upon emergence from the intracellular environment, a
phenomenon termed “fluxing,” some of the cells adopt a filamentous morphology that
allows them to avoid neutrophil phagocytosis and then reattach to the epithelium [17,
18]. Thus, these intracellular bacterial communities may serve as reservoirs for
recurrent infection.
In recent years, our understanding of the interactions between the host and the
pathogen during urinary tract infection has vastly expanded. However, there is a gap
between the body of research knowledge and the realm of clinical practice. Clinical
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interventions for urinary tract infection have essentially not changed for decades. With
the increasing prevalence of antibiotic-resistant organisms, and in light of the
knowledge that some bacteria in the urinary tract could escape the action of antibiotics
by harboring in epithelial cells, there is a great need for the development of new
therapeutic practices. These advances should take into account all of the knowledge
amassed in the research community about patients who are most at risk for infection,
and should aim to develop prevention methods that could specifically target these
groups. Such advances will likely manipulate different aspects of the interactions
between the host, the pathogen and the environment of the urinary tract.
Relevance of the Microbiota
Communities of microorganisms are being characterized in several body
systems, including the oral cavity, the vagina and the gastrointestinal tract [19]. The
Human Microbiome Project aims to discover the diversity of the microbiota associated
with humans and to determine if there is a common microbiota profile, termed a “core”
microbiota, that is prolific in the population and indicative of health. There is some
evidence that such a core microbiota may exist in the oral cavity, whereas in the vagina
and gastrointestinal tract, much more variation is observed, and there is no obvious
single microbiota profile associated with a healthy state [19].
Nevertheless, there is a plentitude of evidence indicating that our microbiota are
essential for our health. The microbiota in the gastrointestinal tract are particularly wellstudied. Knowledge of this community provides considerable insight into the complex
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interactions between the host and the resident microbiota and reveals a truly symbiotic
relationship. Commensal bacteria in the gut can aid in the production and digestion of
nutrients, allowing hosts to exploit nutrient sources they would otherwise be unable to
utilize [20]. For example, many fermenting bacteria can utilize a wide range of
polysaccharides to produce butyrate, a molecule that serves as a major energy source
for colonic cells [21]. In studies performed with germ-free mice, it has been shown that
establishing and maintaining a microbial community in the gastrointestinal tract is
essential for proper immune system development and function [22]; the microbiota
modulate the activity of dendritic cells [23] and T-cells [24] and can contribute to
proper immune balance through the induction of anti-inflammatory effectors [25].
Interaction of the microbiota of the GI tract with the host mucosa provides protection
against intestinal damage by inducing expression of different genes through TLR
signaling [26]. There is also evidence that the presence of particular microbes in the
flora may impart some protection against pathogenic bacteria [27] either by
competitively binding and inhibiting their adherence [28], competing for nutrients [29]
or by inhibiting the proliferation of the pathogen through the production of
antimicrobial compounds [19].
Similarly, in the vagina, Lactobacillus is often the predominating genus, and is
thought to inhibit the growth of invasive bacteria through the production of hydrogen
peroxide, by maintaining a low vaginal pH through the production of lactic acid, and by
competitively filling an ecological niche [30]. However, this equilibrium can be disturbed
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when Lactobacillus loses its prominence, and is instead replaced by predominantly
anaerobic bacteria. Women with this bacterial profile are much more susceptible to a
number of urogenital diseases, including bacterial vaginosis, yeast infections, sexually
transmitted infections including HIV [31] and Neisseria gonorrhoeae [32], and urinary
tract infections [30].
The example of Lactobacillus in the vagina demonstrates that the microbiota can
have a profound influence on the host. The opposite also is true: host factors can play
an integral role in shaping the microbial community [33]. For example, host genetics can
play a role in microbial diversity. In one study, decreased diversity was reported to
correlate with a mutation in a gene associated with familial Mediterranean fever [34].
Furthermore, gut microbes are controlled by diverse immune effectors, such as the
adaptive immune effector secretory IgA, and the innate immune effectors antimicrobial
peptides [35, 36].
An imbalance in the dynamic equilibrium between the host and microbiota can
lead to disease. In many cases, it is not clear if the disruption in the bacterial community
precedes or results from disease and whether the microbiota disruption is the cause.
However, in some cases, the causative relationship is fairly clear. Antibiotic use
profoundly perturbs the intestinal microbiota composition, interfering with many
important interactions between members of the bacterial community and with the host,
often resulting in antibiotic-associated diarrhea (AAD) [37]. In many cases, this
perturbation allows an opportunistic pathogen to gain a foothold and cause disease. The
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most common example of this is Clostridium difficile, the leading cause of pathogenassociated AAD [38]. This association between disruption of the microbiota and
Clostridium difficile infection gives rise to the idea that restoring the intestinal
microbiota to its pre-antibiotic status could be beneficial in reestablishing healthy
interactions, a concept supported by the effective treatment of recurrent C. difficile
infections by inoculating patients’ GI tracts with donor stool specimens [39].
Although much is known about the dynamics of the microbiota at several body
sites like the GI tract, little is known about the microbiota found in the urinary tract.
Current dogma states that the urinary tract and the urine within are sterile [40]. This
dogma arose, largely because clinical practice is to identify infecting organisms via
culture techniques, which do not grow organisms in the absence of infection. However,
this concept of sterile urine could merely be due to the fact that a vast majority of
bacteria are not culturable using these standard laboratory techniques [19]. Even
normally culturable organisms can enter a state in which they are viable, but not
culturable [41], and bacteria in this state have been documented in the urine [42]. The
culture method provides incomplete and skewed information about the bacteria in any
sample. On the other hand, molecular methods, in use for decades as a means of
identifying bacteria in the environment [19], provide much more depth and thus a much
more complete picture of the bacterial community in any sample.
In fact, recent studies offer culture-independent evidence of bacteria in both the
male [43, 44] and female urinary tracts [45, 46]. DNA sequencing technology allows us
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to detect and identify bacteria based on the presence of 16S rRNA genes even in
culture-negative urine. Given the evidence that interactions between members of the
microbiota and the host play a significant role in health and disease [47], the discovery
of bacteria in the urinary tracts suggests the likelihood that a similar dynamic
environment exists there. Supporting this idea is evidence that, in males, certain urinary
microbiota profiles dominated by fastidious, anaerobic and uncultivated bacteria can be
associated with the presence of sexually transmitted infections [44]. Interstitial
cystitis/bladder pain syndrome (IC/BPS) is a urinary tract disorder with unknown
etiology. Some studies report an association of low-count microorganisms with IC/BPS
[48], whereas other studies exclude the possibility of an infectious etiology for IC/BPS
[49]. However, all of these studies utilized culture-techniques. Culture-independent
methods might bring clarity to the question of whether bacteria are responsible for
IC/BPS. It is conceivable that urinary tract diseases with previously unknown etiologies
may be caused by disruptions in the balance between the normal microbiota and the
host’s defenses.
Antimicrobial Peptides
Antimicrobial peptides (AMPs) are small (i.e. ~10-40 amino acids) cationic,
amphipathic peptides that serve as an integral component of our innate defense
system. They exhibit broad-range killing activity against Gram-negative and Grampositive bacteria, fungi, protozoa, and enveloped viruses [50]. Several AMPs are
expressed by humans. Some of the best studied are alpha- and beta-defensins,
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cathelicidin (LL-37), RNase 7, hepcidin, cathelicidin and psoriasin (S100A7). The
observation that organisms throughout the plant and animal kingdoms produce AMPs
suggests that they are evolutionarily ancient and serve an essential role in the defense
of many species from infection. In humans and other mammals, they are expressed by
epithelial cells on the skin and at other mucosal surfaces, as well as in granules of
phagocytic cells [51]. Different classes of AMPs can work together synergistically to
provide additional antimicrobial activity [52]. As such, they constitute one of our first
lines of defense against infection. AMPs can recognize and destroy invading pathogens
even before an inflammatory response is mounted and before innate immune cells,
such as neutrophils, are recruited to the site of infection. Furthermore, they protect
against invasive pathogens long before the adaptive immune system can mount an
antigen-specific response [51, 53-55].
The cationic and amphipathic properties of these molecules are important
because they allow AMPs to recognize and interact with microbial membranes, cause
membrane disruption, and thus ultimately kill the target microbe. Positively charged
AMPs can distinguish microbial membranes from host cell membranes because the
former generally contain phospholipids with negative head groups in the outer
membrane leaflet, while the latter contain phospholipids with no net charge [51, 55].
There are a few proposed models for the mechanism of membrane disruption.
The Shai-Matsuzaki-Huang models describe two potential mechanisms. In the barrelstave mechanism, low numbers of peptide interact with a target membrane via
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electrostatic interactions and polymerize to form a pore in the membrane, causing the
cell to lose membrane potential and allowing contents of the cell to leak out. The carpet
mechanism states that the peptides, when present at high enough concentrations, will
spread out across the surface of the membrane causing a loss of membrane curvature
and leading to the formation of transient toroidal pores [56-58]. Supporting these
concepts is evidence that the hydrophobic portion of LL-37 inserts into the core of a
lipid bilayer altering the capacity of the lipids to pack together properly [59]. In any of
these cases, the integrity of the cellular contents is compromised allowing for rapid lysis
of the target cell [51, 55, 60]. There is additional evidence that once the membrane is
permeabilized, peptides can enter the cell and associate with intracellular targets,
inhibiting cell-wall, nucleic acid or protein synthesis or inhibiting enzymatic activity [60].
More recently, it has been reported that AMPs also serve as important signals
for the immune system, recruiting immune cells to sites of inflammation and helping to
enhance host immune activity by inducing the expression of pro-inflammatory cytokines
and chemoattractant molecules [50, 55]. Cathelicidin, in particular, acts as a chemokine
for neutrophils, monocytes, mast cells and T-cells [61], and can affect transcription of
cytokines by macrophages and keratinocytes [62]. Additionally, it plays an important
role in wound healing, as it stimulates re-epithelialization of skin wounds [63] and
promotes angiogenesis [64]. Human α-defensins can chemoattract T-cells and induce
the release of IL-8 from epithelial cells [65]. β-defensin-3 (hBD-3) stimulates monocytes
to produce the important inflammatory response mediators, IL-6, IL-8 and IL-1β [66]. In
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human oral epithelial cells, β-defensins stimulate the secretion of the lymphocyte
chemoattractant MIP-3α [66]. Recently, it was shown that β-defensin-1 (hBD-1) induces
neutrophils to form neutrophil extracellular traps (NETs), webs of DNA that trap and kill
pathogens [67]. Thus, AMPs induce a variety of immune processes and play additional
roles in host defense apart from their directly antibacterial activities.
Much is also known about the signals that lead to AMP expression. Production of
AMPs can be constitutive, or production can be induced by various stimuli. For example,
hBD-1 is constitutively expressed [68-71]. In contrast, cathelicidin, β-defensin-2 (hBD-2)
and psoriasin are each induced by the activation of host cell receptors that recognize
danger-associated molecular patterns (DAMPs), including pathogen-associated
molecular patterns (PAMPs) [61, 68, 70-72]. For example, hBD-2 expression is induced
by TLR-2 and TLR-4 activation in intestinal epithelial cells [73]. Flagellin-stimulated
activation of TLR-5 induces the expression of hBD-2 and psoriasin in epidermal
keratinocytes [72]. Activation of TLRs results in an intracellular signaling cascade, leading
to the activation and nuclear translocation of NF-κB. This transcription factor upregulates transcription of various genes, including many AMPs and proteins involved in
AMP-dependent responses [50]. Expression of these inducible AMPs also responds to
cytokine stimulation and other signals. In intestinal epithelial cells, hBD-2 expression is
induced by IL-1α. In monocytes, both hBD-2 and cathelicidin are induced by IFN-γ [74].
In addition, the promoter for the cathelicidin gene contains a vitamin D response
element (VDRE) and expression of this peptide is strongly induced by the active form of
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vitamin D, 1,25-dihydroxyvitamin D3 [75, 76]. Vitamin D-dependent signaling also serves
as a pathway through which cathelicidin and TLR-2 expression can be upregulated in
response to injury [77]. Thus, AMPS can be induced by invading pathogens, or by other
signs of stress, such as inflammation or injury.
AMPs affect the composition of the resident microbiota, as discussed above, but
microbes have developed mechanisms for influencing the function or expression of host
AMPs for their own benefit. One example of a resistance mechanism against AMPs is
found in Proteus mirabilis, a major uropathogen as previously discussed. This organism
secretes a metalloprotease, ZapA, with a wide range of targets including AMPs.
Secretion of ZapA allows P. mirabilis to degrade and thus escape several immune
elements [78]. On the other hand, the commensal organism Staphylococcus epidermidis
actually induces the expression of AMPs, including hBD-2 and 3, in keratinocytes on the
skin via a TLR-2-dependent mechanism. This interaction is beneficial for both the host
and microbe, because the AMPs kill pathogens on the skin, protecting the host from
infection, and allowing S. epidermidis to proliferate with fewer competitors for
resources [79].
Nearly all AMPs are synthesized as pro-proteins and undergo a series of
proteolytic processing steps before reaching their bioactive form. Cathelicidin’s
proform, for example, consists of two domains, the C-terminal domain which, when the
peptide is cleaved, goes on to become the mature antimicrobial peptide, and the Nterminal “cathelin-like” domain. Until recently, it was not known that this cathelin-like
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domain actually exerts effects of its own; it exhibits antimicrobial activity against E. coli
and methicillin-resistant S. aureus, and additionally displays protease inhibitory activity,
possibly serving to mitigate tissue damage during inflammation [80]. The proteases
responsible for cleaving cathelicidin into its mature form are the serine proteases
kallikreins 5 and 7. These enzymes are also responsible for further processing mature
cathelicidin into shorter peptides with various antimicrobial and immune signaling
activities [81]. The expression of these kallikkreins in keratinocytes is upregulated by
calcium, vitamin D3, and by retinoic acid [82]. Alpha-defensins are detectable as a 7kD
prodefensin in granulocytic cells and macrophages before they are processed to their
mature 3.5kD form, although the enzymes responsible for this processing are not known
[71].
There is much still to learn about the role of antimicrobial peptides in the urinary
tract. Their importance in this system is shown by knock-out animal models. Both
cathelicidin-deficient (Camp-/-) mice and β-defensin-1 deficient (Defb1-/-J) mice are more
susceptible to UTI than their wild-type counterparts. In humans, hBD-1 is constitutively
expressed by epithelial cells in the kidney [69], while hBD-2 is induced in these cells by
infections [83]. Other AMPs that have been identified in the urinary tract include αdefensins derived from neutrophils, and hepcidin which serves dual roles. It is directly
antimicrobial, and it also regulates iron availability, reducing the amount available for
invading microbes [83]. However, the specific roles these peptides play in disease and
infection of the urinary tract has not been entirely elucidated.
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Concluding Remarks
Given all that we know about the dynamic interactions between the host, the
commensal members of the microbial flora and the pathogens in various body systems, I
hypothesize that careful analysis of interactions between these diverse players in the
urinary tract will yield fruitful information about disease and infection. Analyzing urinary
AMPs, a factor of host defense, and the urinary microbiota in our population of POP/UI
surgery patients may reveal that certain characteristics in these profiles are indicative of
risk for postI-UTI. Identifying who is at risk will be an important step toward being able
to prevent these infections through improved therapeutic intervention.
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CHAPTER TWO
MATERIALS AND METHODS
Sample Collection and Processing
We collected transurethral catheterization (TUC) urine samples from POP/UI
surgery patients at the time of surgery under an IRB approved protocol. Samples were
held on ice no longer than 4 h before distribution in 3 parts. One fraction was sent to
the Loyola University Medical Center clinical microbiology laboratory, which determined
the culture status. One fraction was processed for DNA sequencing by the addition of a
DNA stabilizing agent. This fraction was then frozen at -80°C until it was shipped to the
Nelson laboratory at Indiana University-Bloomington, where it was sequenced. A third
fraction was centrifuged at 13,300 rpm for 20 minutes and the supernatant was filtered
through a .22um filter to remove particulate matter and cell debris. To solubilize
peptides in the urine and to inhibit any proteases that may be present, 10%
trifluoroacetic acid (TFA) was added to each sample to acidify it by reducing the pH to
approximately three, which yields a final 0.1-0.5% TFA concentration. After the initial
processing steps, the samples were aliquoted and stored at -80°C until further analysis
steps.
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Enzyme-Linked Immunosorbent Assays (ELISA)
To measure the concentration of each AMP, I used ELISA kits for human βdefensin-1 (PeproTech, Cat # 900-K202) and psoriasin (Circulex, Cat # CY-8073) and
followed the manufacturers’ instructions.
For the hBD-1 kit, a 96-well plate was incubated with a capture antibody
overnight and then blocked with 1% BSA for one hour. Samples and standards were
incubated for two hours and then concentrations of the target peptide were measured
with a biotinylated detection antibody incubated for two hours, which was itself
detected with an avidin-HRP conjugate incubated for 30 minutes, and its substrate 2,2'azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (green) incubated for approximately
45 minutes. Absorbances were monitored at five minute intervals with a plate reader at
405 nm with wavelength correction set at 650 nm until the absorbance for the highest
standard at 405 nm reached an OD of 1.2.
For the psoriasin kit, samples and standards were incubated for one hour in a 96well plate that had been pre-coated with capture antibody. An HRP-conjugated
detection antibody was added and incubated for one hour. The substrate was then
added and the plate was allowed to develop for 10-20 minutes before 1N H2SO4 was
added to stop the reaction. Absorbance was measured with a plate reader at 450nm
with wavelength correction set at 540 nm.
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Values were normalized to the total protein in each sample as measured by a
Bradford protein assay (Bio-rad, Cat # 500-0006). Dye-reagent was added to the samples
at a 1:5 ratio and mixed well. Absorbance was measure with a plate reader at 595 nm.
High Pressure Liquid Chromatography (HPLC)
Using a Shimadzu HPLC machine, samples were injected onto a C18 column
(Thermo Scienctific, Cat # 25008-254630) in 90% water, 10% acetonitrile (ACN) mobile
phase buffer. Over the course of 50 minutes, the concentration of ACN was increased to
90%. As the concentration increased, increasingly hydrophobic peptides eluted off the
column. A UV detector at 214 nm measured the peptide bonds, and a UV detector at
280 nm measured aromatic side chains of amino acids. Fractions of eluate were
collected at one-minute intervals between 10% and 55% ACN. To ensure each fraction
contained enough peptide for further analysis, three 1.5 mL aliquots were run
separately, and the fractions from each run were combined.
Radial Diffusion Assay (RDA)
Corresponding fractions from each sample were lyophilized to remove residual
acetonitrile, reconstituted in sterile water, and vortexed for one hour at 4°C to fully
dissolve the peptides. The peptide concentration of each fraction was measured by a
spectrophotometer at 214 nm. Then, more sterile water was added, such that
corresponding fractions from each sample contained the same peptide concentration.
For the agar plate, 100 µL of a 108 CFU/mL culture of ΔmprF S. aureus were added per
25 mL of 0.75% Top agar, and 10 mLs of agar were poured in a plate and allowed to
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solidify. Wells were made in the agar with vacuum suction through a sterile Pasteur
pipette. One microliter of each HPLC collected fraction was added to individual wells.
Positive controls were 100 µM synthetic catestatin and 64 µM synthetic cathelicidin,
and water was used as a negative control. The plates were incubated overnight at 37°C.
The area of each zone of inhibition was measured using ImageJ software.
Protease Assay
To assess protease activity, an Enzchek protease assay (Invitrogen, Cat # E6638)
was used, following manufacturer’s instructions. Briefly, samples were incubated with
BODIPY-FL, a macromolecule containing multiple fluorescent markers that are quenched
when the molecule is intact. Upon proteolytic cleavage, a green fluorescent signal was
released. Fluorescence was measured with a microplate reader with excitation and
emission filters of 485 nm and 530 nm, respectively.
16S Sequencing and Bioinformatics
Bacterial DNA sequencing and bioinformatics to determine the identity of
microbes present in urine samples were performed by our collaborators Dave Nelson
and Qunfeng Dong, respectively, as described [45]. Briefly, the V1-V3 regions of the
bacterial 16S rRNA gene were PCR-amplified, bar-coded and sequenced via
pyrosequencing using the Roche 454 Titanium platform. The resulting sequences were
analyzed using a BLAST search to identify and discard any sequences with too great a
homology to human genes, and the remaining sequences were assigned taxonomic
classifications using RDP Classifier v.2.2.
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Statistical Analyses
To facilitate integrated analyses of several different types of data, I have
constructed a database that includes clinical information about each patient, the
patients’ responses to a questionnaire that describes the severity of their symptoms,
the levels of AMPs in their urine and data about their microbiomes, including culture
status and sequencing data. With the help and direction of Qunfeng Dong, our
bioinformatician collaborator, we clustered patients based on similarities of their
microbiota using a Spearman’s rank correlation coefficient as a distance measure. A
series of univariate and multivariate linear regressions were performed to identify
correlations between levels of AMPs and the abundance of certain microbes.

CHAPTER THREE
EXPERIMENTAL RESULTS
Urinary Antimicrobial Peptide Levels
A subset of POP/UI surgery patients will contract a postI-UTI within six weeks of
surgery. Currently, before surgery, there is no way to identify patients who are at risk
for a postI-UTI. Because AMPs are antimicrobial agents, we hypothesize that high or low
levels of one or more urinary AMPs may indicate risk for development of a postI-UTI.
We therefore compared the AMP levels in the following three cohorts:
1) Baseline-positive, i.e. patients with culture-positive urine on the day of surgery
(n = 13)
2) Baseline-negative, i.e. patients with culture-negative urine on the day of surgery
who DO NOT develop postI-UTI (n = 122)
3) PostI-UTI, i.e. patients with culture-negative urine on the day of surgery who DO
develop a postI-UTI (n = 8)
Before we could perform this comparison, however, we had to normalize the
urinary AMP concentrations to account for dilution of the urine due to differences in
patient solid and liquid consumption. One valid approach is to normalize urinary AMP
levels to the total protein content of the urine. Through trial and error, we discovered
that some components in the urine (e.g., creatinine, uric acid or various amino acids)
23
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might interfere with the mechanisms of some of the more commonly used protein
assays and thus lead to false positive results. For example, agents with reducing
potential, chelating agents, and strong acids or bases are known to interfere with BCA
assays and Lowry assays, because their method of protein detection involves the
chelation of a metal ion.
To identify the protein detection method most appropriate for urine, we
measured six samples with three different assays: a Bradford assay, a modified Lowry
assay, and a BCA assay. The values from each assay drastically differed even when using
the same BSA standard concentrations for each assay (Figure 1). Because no two assays
produced similar results, we were unsure which method yielded the most accurate
values. We therefore submitted the samples to the clinical core lab at Loyola. They
measured the protein content of each sample on the Beckman Coulter Synchron DxC800
system, which uses pyrogallol red and molybdate to form a purple color complex with
protein that is detectable by measuring absorbance at 600 nm. For each sample tested,
the results were reported as <60ug/mL, which is their lower limit of detection (data not
shown). These results agreed most closely with the results obtained with the Bradford
assay, which by far gave the lowest values. Thus, we concluded that the Bradford assay
was the most accurate method to measure urinary protein and for the remainder of this
study, we used the Bradford assay to normalize all of the AMP concentrations.
To measure the concentrations of the known urinary AMPs, hBD-1 and psoriasin,
I performed ELISAs. The hBD-1 concentrations varied considerably within each cohort
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B

Figure 1. Protein assay comparison with same samples reveals
discrepancies between assays. (A) The same urine samples tested
with three protein assays: a Bradford assay, a modified Lowry assay
and a BCA assay. (B) Results from the Bradford assay alone.
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and no significant differences were detected (Figure 2a). Between cohorts, the average
levels of hBD-1 and the distributions of those levels were very similar, with a vast
majority of the samples exhibiting minimal levels and fewer samples exhibiting greater
levels of hBD-1. While the concentrations of psoriasin were much lower than those of
hBD-1 (Figure 2b), the levels of psoriasin generally followed a similar pattern, with the
majority of the samples exhibiting very low levels and a small proportion displaying
higher levels. In contrast to those of hBD-1, however, psoriasin levels tended to be
higher in baseline-positive urine than in the baseline-negative urine, although the
differences were not significant. Moreover, baseline-positive psoriasin levels
demonstrated a bimodal distribution. A larger subset of patients in the culture-positive
cohort expressed relatively high levels of psoriasin, whereas the rest expressed minimal
levels. Urinary psoriasin was minimal in all patients who were culture-negative at
baseline, but later contracted a postI-UTI.
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Figure 2. Urinary antimicrobial peptides, human β-defensin-1 and psoriasin,
exhibit great variability. Concentrations of hBD-1 (A) and psoriasin (B) in urine
samples from patients in three cohorts as measured by ELISA and normalized to
total protein levels. Data points represent mean values of two independent
ELISAs performed with each sample.
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Urinary Antimicrobial Peptide Activity
HBD-1 and psoriasin are just two of the many AMPs that could be present in
urine. Furthermore, the amount of AMPs present in the urine does not necessarily
relate directly to their activity. Mutations in the genes that encode AMPs or the genes
that encode the proteins responsible for correctly processing AMPs can cause different
individuals to express AMPs with different functional capacities or, in other words,
different antimicrobial activities. By comparing the functional capacities of AMPs in
urine samples obtained from patients from all three patient cohorts, we may reveal that
higher or lower levels of antimicrobial activity are indicative of risk for postI-UTI. To
assess the antimicrobial activity of AMPs in each urine sample, we fractionated the
peptides within a sample by HPLC and then performed a solid-phase bacterial-growthinhibition assay, the radial diffusion assay.
To determine when we could expect AMPs to elute off the C18 column during
HPLC, we ran through the column three solutions of known AMPs. As expected, because
of their amphipathic nature, the three AMPs, psoriasin, hBD-1 and cathelicidin, eluted
off the column at an intermediate concentration of acetonitrile in the mobile phase
buffer, between 40% and 55% acetonitrile (Figure 3a-c). Amphipathic peptides from a
urine sample eluted between 10% and 55% acetonitrile; therefore, to separate the
peptides contained in one sample, fractions were collected at one minute intervals
between these concentrations, which corresponds to minutes 10-35 during one
fractionation run (Figure 3d).
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Figure 3. Antimicrobial peptides and urinary peptides elute at various acetonitrile
concentrations during HPLC. (A-C) Three known AMPs elute between 40% and 55%
concentration of acetonitrile in water. (D) Urinary AMPs elute between 10% and
55% concentration of acetonitrile in water. Shaded bars indicate one-minute
intervals in which fractions of eluate are collected.

30

I compared the tracings between samples from each of the three cohorts.
Although not universally the case, the HPLC tracings of baseline-positive urine samples
tended to show larger and more frequent peaks than baseline-negative urine (Figure 4),
indicating that, in general, culture-positive samples contain a greater variety and higher
concentrations of peptides and proteins.
The next step in determining the functional capacity (i.e., antimicrobial activity)
of urinary AMPs was to subject each HPLC fraction to a radial diffusion assay. This assay,
which measures antimicrobial activity through bacterial growth inhibition, was
performed with fractions of a subset of urine samples from each cohort. Antimicrobial
activity was tested against a ΔmprF Staphylococcus aureus strain. Multiple peptide
resistance factor (mprF) is a bacterial membrane protein that regulates membrane
charge by synthesizing and transferring positively charged lysyl-phosphatidylglycerol to
the outer leaflet of the cell membrane. Strains with mprF mutations have more
negatively charged membranes making them more susceptible to cationic AMPs [84].
We use this strain, because its susceptiblity to AMPs makes it easier to observe
differences in antimicrobial activity.
Urinary peptide fractions from baseline-positive samples tended to exhibit
greater frequency and magnitude of antimicrobial activity against ΔmprF S. aureus than
peptide fractions from baseline-negative urine (Figure 5); however, in all three cohorts
there were samples that did not exhibit antimicrobial activity against this strain in any
fractions. In this regard, there are no obvious differences between the cohort of
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baseline-negative patients who develop a postI-UTI (postI-UTI positive) and the cohort
of baseline-negative patients who do not. Of the samples that exhibited antimicrobial
activity, some trends are apparent. For example, certain fractions more frequently
exhibited antimicrobial activity (e.g., fractions 14-16, 24 and 33-34).
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Figure 4. Baseline-positive urine tends to contain a greater variety and higher
concentrations of protein and peptides than baseline-negative urine. (A) HPLC
tracings of two baseline-positive urine samples. (B) HPLC tracings of two baselinenegative samples, one from a patient who contracted a postI-UTI, and one from a
patient who did not. Tracings are representative of their corresponding cohort,
although not all samples in one cohort always followed the trend.
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Figure 5. Baseline-positive urinary peptide fractions exhibit greater
antimicrobial activity. Each column shows corresponding fractions from the
samples listed along the left. Also noted on the left is the identity of the cultured
bacteria either in the sample (baseline-positive) or the bacteria cultured from
the patient within six weeks after surgery (postI-UTI). Values show the area of
the zone of inhibited growth in square millimeters around fractions that were
normalized to corresponding fractions from other samples so that all contained
the same peptide concentration. Darker blue indicates a larger zone of inhibition
around that fraction.

AMPs undergo various stages of proteolytic processing. They are synthesized as
pro-proteins, which are then cleaved into their bioactive form. Further cleavage
degrades them. Because proteases are responsible for the processing of AMPs to their
mature form, antimicrobial activity is integrally associated with protease activity.
Measuring total protease activity in a sample may reveal that altered protease activity is
associated with higher or lower antimicrobial activity, giving insight into a possible
mechanism for that altered antimicrobial activity. To measure total protease activity, an
Enzchek protease assay was performed on a few samples. In this preliminary study,
protease activity trended toward higher levels in baseline-positive urine than in
baseline-negative urine (Figure 6). Due to limited sample numbers and volumes, further
analyses with this assay were not performed.
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Figure 6. Urinary protease activity trends toward higher levels in
baseline-positive urine than in baseline-negative urine. Preliminary
3
results of protease activity as measured by fluorescence in baselinepositive and baseline-negative urine (baseline-negative, n = 4;
baseline-positive n = 6; Bars represent mean ± SEM; Analyzed by
Student’s t-test, p = 0.0525)
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Urinary Microbiota
AMPs, an arm of host innate immunity, are known to influence the microbiota of
various body sites. This may also be true of the urinary tract. Once could easily imagine
that disruption of the commensal members of the resident urinary bacterial community
might lead to pathological disease. To assess the likelihood of this scenario, we first
must characterize the urinary microbiota, attempting to identify “abnormal” or high-risk
microbiota profiles. Microbiome analysis was performed in collaboration with Dave
Nelson, whose research group performed the amplification and sequencing of bacterial
DNA, and Qunfeng Dong, whose group provided the bioinformatic analysis of the
resulting data
Sixty-three urine samples were analyzed for bacterial 16S DNA sequences. Of
those 63 samples, 46 (73%) contained high-quality evidence of bacterial DNA, while 17
(27%) samples contain no conclusive evidence of bacterial DNA. In all of the samples
with evidence of bacterial DNA, we identified 18 phyla, 100 families, 177 genera, and
1942 operational taxonomic units (OTUs). Figure 7 shows a phylogenetic tree of the two
hundred most frequently sequenced OTUs. This illustration, along with the fact that
1,942 OTUs were sequenced in total, demonstrates that bacteria are present and
common in urine, in contrast with the previous dogma of sterile urine. Also of interest is
the prevalent number of species, or OTUs, that are not associated with any previously
identified species. This reveals that our previous view of the urinary tract microbial
community, informed by culture techniques, was not comprehensive.
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Figure 7. Genetic diversity of urinary microbiota. The two hundred most
frequent OTUs in all urine samples analyzed. Due to space limitations, a great
number of less frequent OTUs are not shown.
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To gain a better picture of the urinary tract microbiota, heat maps were created
showing the abundance of sequences of the fifteen most abundant bacterial families
(Figure 8) and the tweny most abundant genera (Figure 9) within each sample. These
heatmaps revealed that some bacteria tend to be present together. For example, at the
family level, Corynebacteriaceae and Incertia Sedis XI tend to occur together. At the
genus level, Corynebacterium and Anaerococcus tended to be present together, and
Peptoniphilus and Dialister appeared together, also.
To determine if the microbiota of patients in each cohort were similar, we
performed a cluster analysis at the family and genus taxonomic levels (Figure 8 and 9).
Although the number of baseline culture-positive and postI-UTI samples was small (n=1
and n=2, respectively), it appears that, in terms of their microbiota profiles at the family
and genus levels, the two postI-UTI samples were more similar to one another than to
any other samples analyzed. At the family level, the two postI-UTI samples also
clustered near the one baseline-positive sample. These results indicate that, in a broad
sense, their microbiota are similar to the baseline-positive sample. One prominent
family that was prevalent in baseline-negative, postI-UTI negative urine and absent in
the samples similar to the baseline-positive or postI-UTI positive urine was
Lactobacilliaceae. Corynebacteriaceae was another family that tended to be present in
the urine of baseline-negative patients.
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Figure 8. Microbiota profiles of postI-UTI and baseline-positive samples at the family
level are similar. Hierarchical heatmap showing abundance of bacteria of the fifteen
most abundant families. Sequences in these families account for greater than 90% of
all sequences in all samples analyzed. Green indicates lower abundance; red indicates
higher abundance. Cluster analysis (shown at top of figure) clusters together samples
based on similarities in the microbiota profiles using Spearman’s Rank coefficient as a
measure of distance.
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Figure 9. Microibiota profiles of postI-UTI positive samples at the genus level
are similar. Hierarchical heatmap showing abundance of the twenty most
abundant genera of bacteria. Cluster analysis (shown at top of figure) clusters
together samples based on similarities in the microbiota profiles using
Spearman’s Rank coefficient as a measure of distance.
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Integrated AMP and Microbiota Results
Given that urinary tract infections are likely the result of an imbalance amongst
factors of the host immune system, pathogens and commensal bacteria that shape the
environment of the urinary tract, studying these different aspects in the context of one
another will give us a better understanding of who is at risk for infection and potentially
will lead to new therapeutic options and/or prevention strategies.
Because psoriasin is known to exert its antimicrobial effects against E. coli, I was
interested in whether levels of psoriasin correlated with the presence of E. coli. Indeed,
psoriasin levels were significantly lower in samples with E. coli, detectable either by
culture or by 16S sequencing, than in samples with other types of culture-verified
infections (Figure 9). However, in the group of “other infections” there appears to be
two separate populations, one exhibiting high levels and one exhibiting minimal levels,
indicating that there may be other factors at play that we do not currently understand.
Further analysis revealed additional microbiota characteristics that correlate
with levels of psoriasin. With the help of our collaborator, Qunfeng Dong, a series of
univariate linear regressions were performed examining possible correlations between
levels of psoriasin and individual genera of bacteria. By these analyses, we determined
that numbers of sequences in two genera, Streptococcus and Peptoniphilus, each
individually correlated with increased levels of psoriasin (Figure 10). Since two genera
individually correlated with levels of psoriasin, we next performed a multivariate linear
regression analysis to determine if multiple genera together correlated with levels of
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psoriasin. A group of seven genera, Streptococcus, Peptoniphilus, Finegoldia,
Varibaculum, Peptostreptococcus, Agromonas and Gp3, was identified whose
abundance positively correlated with amounts of psoriasin. It was determined that
variation in the abundance of these seven genera accounted for 91% (adjusted Rsquared = 0.9069) of the variance in levels of psoriasin (p < 0.0001).

Figure 10. Levels of psoriasin are lower in urine with detectable E. coli that in urine
with other types of infections. Levels of psoriasin are shown for urine samples with
E. coli detected either by culture or by 16S sequencing and for urine samples with
another type of culture-detected pathogen. Organisms in the “other infection”
column include Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium
spp. and Enterococcus spp. (Analyzed by Student’s t-test, p < 0.05)
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Figure 11. The number of sequences in the genera Streptococcus and Peptoniphilus
each positively correlate with levels of psoriasin. Levels of psoriasin were compared
to the number of sequences of either Streptococcus or Peptoniphilus with a
univariate linear regression analysis. Streptococcus: R = .206, p = 0.03; Peptoniphilus:
R = 0.182, p = 0.042.

CHAPTER FOUR
DISCUSSION
Taken together, our data provide some insight into possible interactions
between the host, its commensal microbiota and pathogenic microbes. Understanding
these interactions may reveal a profile of risk factors that can identify patients who are
susceptible to postI-UTI. Once we learn the factors that can identify patients at risk, we
can begin to develop an assay to assess these measures in patients, and based on those
measurements, design a course of treatment meant to specifically address the areas in
which the patient is deficient. This assay would serve as an indispensable tool for
clinicians.
Sample Processing
Because dilution of the urine can vary greatly depending on patient
consumption, concentrations of peptides of interest must be normalized. This
normalization permits comparison of values between samples and between cohorts. We
decided to normalize AMP levels to total protein. However, our data demonstrated that
not all protein assays are appropriate for use with urine, as certain compounds in urine
interfere and thus lead to false positive results. For example, some protein assays rely
on a mechanism that involves the chelation of metal ions by protein; thus, any other
compounds that cause chelation of metal ions, such as uric acid, can lead to a false
44
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positive result. When we compared three commonly used protein assays, a Bradford
assay, a modified Lowry assay and a BCA assay, we determined that the Bradford
method was the most appropriate and most accurate, whereas the modified Lowry and
BCA assays yielded results that were much too high. We henceforth used the Bradford
assay to measure protein levels. This finding will be important for all future analyses of
any components of the urine.
The discrepancies between the results of these three different protein assays
help to explain some other results that I obtained during my attempt to determine the
best way to process urine samples for analysis (data not shown). Initially, because I was
worried that debris or extra substances in the samples would interfere with many of our
experiments, I dialyzed each sample with membranes with approximately 3.5 kD pore
sizes. At the time, I was measuring total protein with a BCA assay, and when I measured
protein levels in dialyzed versus undialyzed urine, it appeared that dialysis caused a
significant loss of protein (e.g. 5 mg/mL down to 100 µg/mL). Knowing what we know
now, however, it seems more likely that dialysis actually removed whatever
components in the samples were resulting in false positive results with the BCA assay.
At the time, though, we decided dialysis was an inappropriate processing step, because
it caused too much loss of protein. Now that we know that the BCA assay is an
inappropriate method to measure urinary protein, it may be worthwhile to revisit the
use of dialysis as a processing step to remove interfering substances. If this method is
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used in the future, it may be useful to look into dialysis inserts for 96-well plates that
allow for dialysis of many samples at one time.
To separate AMPs from potentially interfering substances, I next experimented
with the use of centrifuge filters with pore sizes of 3 kD and 30 kD to separate urine
components into three fractions of <3 kD, 3-30 kD and >30 kD. The AMPs would
theoretically fall into the 3-30 kD fraction. Using a BCA assay to measure protein, we
once again found that most of the protein fell into the <3 kD fraction, although we now
think that we were detecting non-protein components.
I also utilized these centrifuge filters to assess whether AMPs in the samples
were fully solubilized. To solubilize the peptides, I began to add trifluoroacetic acid (TFA)
to samples. I measured hBD-1 concentrations in each fraction of urine samples with and
without added TFA. I found that without TFA, most hBD-1 could be found in the >30 kD
fraction. However, with the addition of TFA, most of the hBD-1 would be observed in
the 3-30 kD fraction (data not shown).This indicated to us that the addition of TFA does
help solubilize our peptides of interest, allowing for more accurate measurement by
ELISA. However, not all of the hBD-1 could be found in one fraction, even with the
addition of acid. To accurately measure AMP concentrations in urine, we decided to
forgo the use of centrifuge filters, and simply use a 0.2 µm filter to remove cells and
large debris, and then add TFA to solubilize peptides.
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Urinary Antimicrobial Peptides
Analysis by ELISA revealed a wide range of hBD-1 levels in the patients who were
culture-negative on the day of surgery and did not contract a UTI (baseline-negative),
the patients who were culture-positive on the day of surgery (baseline-positive), and the
patients who were culture-negative on the day of surgery but became culture-positive
after surgery (postI-UTI). Since the distributions were not significantly different, we
concluded that hBD-1 could not distinguish the three cohorts.
Likewise, ELISA revealed a wide range of urinary psoriasin in the baseline
negative and baseline-positive cohorts. The distribution of the baseline-positive cohort
appeared to be bimodal, with some patients expressing relatively high levels of psoriasin
and some expressing almost none. In contrast, the level of urinary psoriasin in all postIUTI patients was minimal. Since psoriasin expression is generally inducible in the
presence of infection, it is possible that some patients contracted a UTI (postI-UTI)
because they were unable to mount a sufficient response. Unfortunately, low psoriasin
concentration could not be used as a predictor of postI-UTI because it was not restricted
to the postI-UTI cohort.
Future studies of urinary AMPs should include more samples in the baselinepositive cohort and in the postI-UTI cohorts, as this may reveal distinguishing
characteristics in those patients who ultimately come down with infection. It also may
be useful to measure levels of cathelicidin, lactoferrin or hepcidin, three peptides with
demonstrated antimicrobial activity that have been detected in the urinary tract and
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that may play a role during infection. I performed one ELISA for cathelicidin in urine
samples. I was not able to detect any measurable amounts (data not shown); however,
the ELISA kit had not been validated for use with urine samples. Validating a cathelicidin
ELISA for use with urine samples, or determining some other way to quantify urinary
cathelicidin, may be useful for future studies.
Running known antimicrobial peptides on a C18 column during HPLC taught us
where to expect elution of urinary AMPs. Amphipathic peptides in the urine eluted
between 10% and 55% acetonitrile concentration, so we fractionated peptides by
collecting fractions at one-minute intervals in that concentration range. This knowledge
also will be essential for future urine AMP analyses of this kind. We also observed that
baseline-positive urines generally exhibit larger and more frequent peaks in their HPLC
tracings, indicating that those samples contain a greater variety and higher
concentration of peptides and proteins. This is not unexpected, because during infection
the host up-regulates the expression of a variety of genes [12, 14, 15, 23], so one would
expect to see a greater number of gene products.
Included in this host of up-regulated gene products are a variety of AMPs and, as
expected, the overall antimicrobial activities of baseline-positive urinary peptide
fractions against ΔmprF S. aureus was higher than activities seen in baseline-negative
urine. In our small sample size, we did not detect a difference between culture-negative
urine from patients who DO NOT contract a postI-UTI (i.e., baseline-negative) and
culture-negative urine from patients who DO contract a postI-UTI (i.e. postI-UTI).
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Therefore, patients in the postI-UTI cohort could not be identified at baseline based on
differences in the antimicrobial activities of their urinary AMPs against ΔmprF S. aureus.
These data exclude the idea that the reason these patients contract infection is due to
lower antimicrobial activity at the time of surgery; however, these data do not exclude
the possibility that patients who develop postI-UTIs may be defective in their ability to
mount an appropriate AMP response in response to an infective insult.
With this idea in mind, it is worth mentioning that we only tested the
antimicrobial activities of urinary AMPs against the Gram-positive ΔmprF S. aureus. In
the future, antimicrobial activities against other relevant bacteria, such as the Gramnegative E. coli, should also be tested. Such a screen would likely reveal differential
antimicrobial activity profiles. For example, the urine of baseline-positive patient #817
cultured E. coli but exhibited widely distributed antimicrobial activity against ΔmprF S.
aureus. In contrast, the urine of baseline-positive patient #690 also cultured positive for
E. coli, but exhibited a very limited range of antimicrobial activity against ΔmprF S.
aureus. Another immediate area of future interest would be to identify the components
of each fraction by mass spectrometry. This may reveal that certain AMPs are present,
but not active, which could explain an individual’s susceptibility to infection. Mass
spectrometry also may reveal previously unknown AMPs in the urine.
Because proteases play an integral role in processing AMPs from their propeptide forms to their mature forms and in degrading them beyond that, protease
activity can be intimately associated with antimicrobial activity. I was able to perform
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one preliminary experiment assessing urinary protease activity and found that protease
activity trends toward higher levels in baseline-positive urine than in baseline-negative
urine. This may indicate that, in addition to up-regulating AMPs, the host also activates
or up-regulates proteases to facilitate more processing of AMPs to their active forms.
Future studies could expand upon this preliminary experiment to determine if this
phenomenon holds true with a larger sample size, and perhaps to see if lower protease
activity might identify patients at risk for postI-UTI before they undergo surgery. To
determine the role of certain types of proteases, such as the serine proteases that are
responsible for cleaving cathelicidin, a future experiment could include adding inhibitors
for these certain classes of proteases, and observing how much of the total protease
activity disappears. Any future studies on urinary protease activity also may reveal that
it is useful to normalize these results to total protein to account for dilution of the urine
due to differences in patient solid and liquid consumption.
Urinary Microbiota
In parallel with our initial characterization of the AMP profile of the urinary tract,
we have begun to characterize the microbiota profile of the urinary tract. The “normal”
urinary tract is generally considered to be a sterile environment. This dogma is based
upon culture-based analyses. Using culture-independent DNA-sequencing-based
techniques, however, we have shown evidence of bacterial DNA in 73% of the urine
samples analyzed. These results are similar to those previously reported by our research
team [43-45] and others [46].
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A phylogenetic tree of the two hundred most frequent OTUs sequenced provides
some indication of the microbial diversity that exists in the lower urinary tract. While
many of the OTUs correspond to well-known bacterial genera, many of the most
frequent OTUs are unclassified. The fact that so many organisms have not been
previously characterized highlights the insufficiency of the culture-based methods upon
which researchers, clinical microbiologists and clinicians have relied to identify bacterial
residents of the urinary tract [43-46]. This reliance has likely given us a stilted
understanding of the microbial profiles of the lower urinary tract, especially in relation
to health and disease.
Given the existence of urinary bacterial communities, there likely exist countless
interactions among members of this microbiota as well as between the microbes and
their hosts. Of these interactions, we know almost nothing. However, given the
existence of a urinary microbiota, it might be wise to revisit certain clinical situations.
For example, patients with bacterial vaginosis are at higher risk for urinary tract
infection [30]. Could it be that the disruption in the vaginal microbiota associated with
bacterial vaginosis is of secondary importance compared to a disruption in the urinary
microbiota? This idea is supported by the observation that Lactobacillus was often
found in the urine of baseline-negative patients who did not contract a postI-UTI, but
not in the urine of patients that were baseline-positive or contracted a postI-UTI. If this
hypothesis is valid, then antibiotic treatment for bacterial vaginosis could alter the
composition of the urinary microbiota, causing the unintended side effect of UTI.
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To determine whether the urinary microbiota of patients in a given cohort
resembled the microbiota of other patients in that cohort, we performed a cluster
analysis and constructed a heat map. At both the family and genus level, patients in the
baseline-negative cohort clustered into two general groups. At the family level, these
groups appeared to cluster, in part, on the basis of Lactobacilliaceae. In contrast, at the
genus level, Lactobacillus was not a defining feature. This difference warrants further
investigation.
Unfortunately, the number of samples that produced quality sequences for
taxonomic classification limited our analysis of the postI-UTI and baseline-positive
cohorts. In the end, we only had microbiota profiles for two postI-UTI samples and one
baseline-positive sample. It is perhaps telling that, in spite of the small sample size, that
the two postI-UTI samples clustered together at both the family and genus levels,
indicating that their microbiota profiles are more similar to one another than they are to
any other samples. This encouraging result indicates that there may be a characteristic
microbiota profile that can identify patients at risk for postI-UTI before they undergo
surgery. In addition, at the family level these two postI-UTI samples were relatively
similar to the one baseline-positive sample. This similarity may indicate that the postIUTI patients were already on their way to becoming infected: perhaps they were already
colonized with a pathogen, or their urinary microbiota profiles were more conducive for
allowing a pathogen to take hold. For example, members of the Lactobacilliaceae family
were prevalent in many baseline-negative patients who did not develop a postI-UTI, but
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absent in samples similar to the postI-UTI-positive and culture-positive samples. Perhaps
the presence of Lactobacilliaceae is indicative of a healthy state. Being able to identify
patients that are susceptible to infection would be an important step in developing
clinical interventions to prevent these infections from occurring.
We also can interpret the microbiota data by asking which bacteria tend to be
present together. At the family level, for example, Corynebacterium and Incertia Sedis XI
tend to be present together. At the genus level, Corynebacterium and Anaerococcus
tend to pair, and Peptoniphilus and Dialister tend to co-exist. At this time, we are unable
to say if these pairings are clinically relevant, but recognizing trends within the
microbiota will likely be important in understanding microbiota profiles that are
indicative of risk for infection. Further statistical analyses should be performed to
determine if there are any groups of bacteria that exhibit significant correlations, either
positive or negative, with other groups of bacteria.
Future studies of microbiota profiles should analyze more samples from the
postI-UTI and baseline-positive cohorts. In addition, it would be useful to analyze the
microbiota at a lower taxonomic level, such as the species or strain level. It is entirely
possible and likely that certain members of each family and genus are more indicative of
risk for postI-UTI than the entire family or genus. Indeed, some strains of the species E.
coli are pathogenic (UPEC) whereas other strains are commensal (e.g. K-12). While 16S
rRNA gene sequencing can distinguish genus and in certain cases species, it does not
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provide enough depth of information to distinguish between different strains; thus,
other molecular techniques will be needed if such a level of depth is required.
Integrated Analyses
Analysis of AMPs alone did not reveal any characteristics indicative of risk for
postI-UTI. While analysis of microbiota profiles alone revealed some interesting
microbiota profiles that could potentially identify patients at risk for postI-UTI, this line
of investigation requires further exploration. We therefore sought to integrate what we
know about both factors in the urinary tract. The goal was to reveal relationships that
might identify patients at-risk for postI-UTI.
Because psoriasin has been shown to exert its antimicrobial effects against E.
coli, and because E. coli is such a prevalent uropathogen, appearing several times in our
culture-positive samples, we wondered whether levels of psoriasin corresponded with
samples containing E. coli, detectable either by culture techniques or by 16S rRNA gene
sequencing. Psoriasin levels were significantly lower in samples containing E. coli than in
other culture-positive samples. This observation is consistent with the notion that
patients contract an E. coli infection because they are not able to express a sufficient
antimicrobial response to the initial E. coli insult. Indeed, similar results were found in
the lung, where psoriasin levels were found to be elevated in the presence of S. aureus,
but not elevated in the presence of E. coli as detected by culturing bronchoalveolar
lavage fluid [85].
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Our collaborator Qunfeng Dong performed univariate linear regression analysis
on the numbers of sequences of any single genus and the detected levels of psoriasin. In
doing so, he discovered that the numbers of sequences of two genera, Streptococcus
and Peptoniphilus, each positively correlated with levels of psoriasin. A multivariate
linear regression analysis, which is able to account for the combined effect of multiple
genera on the levels of psorasin, revealed that the numbers of sequences of any of a
group of seven genera (Streptococcus, Peptoniphilus, Finegoldia, Varibaculum,
Peptostreptococcus, Agromonas and Gp3) positively correlated with the levels of
psoriasin. In fact, variance in the number of sequences of these genera could account
for approximately 91% of the variation in psoriasin concentration. Psoriasin’s positive
correlation with this defined group of bacteria, and its conspicuous absence in any
samples containing E. coli could indicate that a microbiota containing a combination of
bacteria of these seven genera is protective against E. coli infection. It is possible that
they provide protection by inducing the expression of psoriasin, which is prohibitive for
the colonization and proliferation of E. coli. Such an interaction would mirror
interactions at other body sites, where commensal bacteria induce the expression of
AMPs, consequently protecting the host from infection and removing potential
competitors from the environment, such as Staphylococcus epidermidis does on the skin
[79].
There are any number of future directions in the area of integrated analysis of
AMPs and the microbiota, not the least of which is performing further statistical
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analyses on the data we already have. There are likely other correlations that could shed
light on important interactions; we just need to continue to thoughtfully analyze the
data to glean from it what we can. There are a few other specific questions to address in
the future. One is whether certain genera of bacteria correlate with any other AMPs
besides psoriasin. We could also ask more mechanistic questions about how these
genera induce psoriasin or any other AMP. Other future experiments could involve using
either an animal model of UTI or an in vitro system to ask whether the presence of any
genera associated with higher AMPs is protective against E. coli infection or any other type
of infection.

If we can identify a profile of urinary AMPs and/or microbiota that is associated
with higher risk for postI-UTI, it would then become crucial to develop a tool for
clinicians to rapidly assess levels of AMPs and certain microbes in a single assay. One
possibility would be the development of a multiplex assay that utilizes fluorescent
quantum dots to quantitatively measure levels of different AMPs and levels of bacterial
DNA from certain different bacteria all in the same assay. If there is more than one
profile associated with risk, or if there are different profiles associated with risk for
different types of infection, we could develop a course of treatment that specifically
aims to correct the area in which that patient is deficient.
Importantly, it may prove beneficial to shift our focus away from eradication as a
means of treating infection, and instead treat each body site like the ecologically distinct
environment that it is, and rather focus on maintaining a healthy ecology. In support of
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this idea is the successful treatment of pathogen-associated antibiotic-associated
diarrhea with donor stool samples [39]. This provides an example of how microflora
disrupted by antibiotics providing an ecological niche for a pathogen to take hold can be
restored to a healthy state by reintroducing a healthy balance of microorganisms rather
than by simply trying to eradicate the pathogen. We may find that a good way to treat
and/or prevent urinary tract infections in POP/UI surgery patients is to optimize the
urinary microbiota, perhaps by introducing probiotics to establish populations of
bacteria associated with a healthy state for the host.
Approaching it from a different angle, we may find that providing exogenous
AMPs or artificially inducing expression of AMPs is a more effective way of preventing
infection than prophylactic antibiotics. Another interesting dynamic of AMPs and host
defense is the report that different people have different copy numbers of hBD-2
encoded in their genomes. Low hBD-2 copy number has been linked to Crohn’s disease,
psoriasis and COPD [86], but no similar analysis of hBD-2 copy number has been
performed in relationship to susceptibility to UTI. This could potentially be an
interesting area of future research.
As our understanding grows of the processes and interactions that lead to UTI,
there is a great need to translate our research knowledge into clinical practice. The
strikingly high rate of postI-UTI highlights the need for inventive new therapeutics. Any
areas of future research that seek to translate our understanding into tools that can be
utilized by clinicians will yield great benefits for patients.
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